Recently, METiS Technologies showcased its innovative nucleic acid therapeutic MTS105 for advanced hepatocellular carcinoma at both the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) and the 12th International mRNA Health Conference, drawing widespread attention with its preclinical research data.
At the International mRNA Health Conference, METiS Technologies’ poster, “Organ-Specific Delivery of a mRNA-Encoded Bispecific T Cell Engager Targeting Glypican-3 in Hepatocellular Carcinoma,” was selected from hundreds of submissions and awarded the Outstanding Poster Award. Notably, this conference was organized with the participation of global academic and industry experts, including 2023 Nobel Prize winner Katalin Karikó. This recognition underscores METiS Technologies’ leading capabilities and innovative strength in nucleic acid therapeutics and precision delivery.
MTS105 is an mRNA-encoded bispecific T cell engager (BiTE) developed using METiS Technologies’ first-in-class tumor-targeted LNP delivery platform. Preclinical data demonstrate that MTS105 achieves high local, organ- and tumor-specific expression in the liver while maintaining favorable safety and tolerability. The project is part of the 2022 National Biopharmaceutical Technology Innovation Center’s key nucleic acid drug initiative and officially entered human trials in November 2024, marking a significant milestone in its clinical development.
